New insights for low dosing with the new P2Y12 inhibitors: – Lesson from the east –

Circulation Journal

Volumn 78, Issue 12, 2014, Pages 2840-2842

  Silvain, Johanne ^a   Kerneis, Mathieu ^a   Collet, Jean Philippe ^a   Montalescot, Gilles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR INHIBITOR; TICAGRELOR; UNCLASSIFIED DRUG; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL (TOPIC); DRUG DOSE INCREASE; EDITORIAL; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); PLATELET REACTIVITY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; CORONARY DISEASE; FEMALE; MALE; PERCUTANEOUS CORONARY INTERVENTION;

CORONARY DISEASE; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES;

EID: 84911892410     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-1166     Document Type: Editorial

References (22)

1. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
2. Bellemain-Appaix A, Montalescot G, Silvain J, Barthelemy O, Beygui F, Collet JP, et al. Slow response to clopidogrel predicts low response. J Am CollCardiol 2010; 55: 815-822.
3. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
4. Pena A, Collet JP, Hulot JS, Silvain J, Barthélémy O, Beygui F, et al. Can we override clopidogrel resistance? Circulation 2009; 119: 2854-2857.
5. Cayla G, Cuisset T, Silvain J, O'Connor SA, Kerneis M, Castelli C, et al. Prasugrel monitoring and bleeding in real world patients. Am J Cardiol 2013; 111: 38-44.
6. Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, et al. Clinical implications of very low on-treatment plateletreactivity in patients treated with thienopyridine: The POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv 2013; 6: 854-863.
7. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010.
8. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
9. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003. Erratum in: Eur Heart J 2014; 35: 2260-2261.
10. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011; 305: 1097-1105.
11. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-942. Erratum in: N Engl J Med 2010; 363: 1585.
12. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
13. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data. Lancet 2013; 382: 1981-1992.
14. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
15. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009; 373: 309-317.
16. Erlinge D, Ten Berg J, Foley D, Angiolillo DJ, Wagner H, Brown PB, et al. Reduction in platelet reactivity with prasugrel 5 mg in lowbody-weight patients is noninferior to prasugrel 10 mg in higherbody-weight patients: Results from the FEATHER trial. J Am Coll Cardiol 2012; 60: 2032-2040.
17. Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014; 11: 597-606.
18. Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78: 1684-1692.
19. Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, et al; on behalf of the PRASFIT-Elective Investigators. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery diseases undergoing elective percutaneous coronary intervention: Phase III, randomized, double-blind study. Circ J 2014; 78: 2926-2934.
20. Bellemain-Appaix A, Brieger D, Beygui F, Silvain J, Pena A, Cayla G, et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: A meta-analysis. J Am Coll Cardiol 2010; 56: 1542-1551.
21. Silvain J, Cayla G, Hulot JS, Finzi J, Kerneis M, O'Connor SA, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: The SENIOR-PLATELET study. Eur Heart J 2012; 33: 1241-1249.
22. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297-1309.